Enrolling by invitationPhase 2NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Taiho Oncology, Inc.
- Intervention
- ASTX727(drug)
- Enrollment
- 332 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- Compassionate Care Research Group, Fountain Valley, California, United States
- Boca Raton Clinical Research, Plantation, Florida, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
- Cancer and Hematology Centers for Western Michigan, Grand Rapids, Michigan, United States
- Mayo - Rochester, Rochester, Minnesota, United States
- Hackensack Medical Center - 06 FE Study, Hackensack, New Jersey, United States
- Hackensack Medical Center, Hackensack, New Jersey, United States
- Rosewell Park Cancer Institute, Buffalo, New York, United States
- Roswell Park Cancer Institute - 06 FE Study, Buffalo, New York, United States
- Gabrail Cancer Center Research - 06 FE Study, Canton, Ohio, United States
- Gabrail Cancer Center Research, Canton, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Charleston Hematology Oncology Associates, Charleston, South Carolina, United States
- Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04093570 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center